# US 2017/0360817 A1 · Use of aminoglycoside analogs in the treatment of rett syndrome

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0360817 A1
- Document ID: US20170360817A1
- Status: Published application
- Kind: A1
- Application number: 15/316,209
- Filed: 2015-06-04
- Published: 2017-12-21
- Earliest claimed: 2014-06-05
- Assignees: Eloxx Pharmaceuticals Ltd.
- Applicants: Eloxx Pharmaceuticals Ltd.
- Inventors: Timor BAASOV; Shmuel TUVIA; Dori PELLED
- Web page: https://patentgrep.com/patent/US20170360817A1

## CPC

- A61K 31/7036: having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compounds, methods and uses of pseudo-trisaccharide aminoglycosides represented by the general formula I: or a pharmaceutically acceptable salt thereof, wherein R1 is selected from the group consisting of alkyl, cycloalkyl and aryl; and all other variables and features are as described in the specification, in the treatment of Rett syndrome are disclosed.

## Claims

### Claim 1

A method of treating Rett syndrome in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound represented by formula I:
or a pharmaceutically acceptable salt thereof,
wherein:
R1 is selected from the group consisting of alkyl, cycloalkyl and aryl;
R2 is hydrogen or (S)-4-amino-2-hydroxybutyryl (AHB);
R3 is selected from the group consisting of hydrogen, alkyl, cycloalkyl and aryl;
a stereo-configuration of position 5″ is an R configuration or an S configuration; and
a stereo-configuration of position 6′, when chiral, is an R configuration or an S configuration.

### Claim at position 2

2-4. (canceled)

### Claim 5 (depends on 1)

The method of claim 1, wherein R1 is alkyl.

### Claim 6 (depends on 5)

The method of claim 5, wherein said alkyl is methyl.

### Claim 7 (depends on 1)

The method of claim 1, wherein R2 and R3 are each hydrogen.

### Claim 8 (depends on 1)

The method of claim 1, wherein R2 is AHB and R3 is hydrogen.

### Claim 9 (depends on 1)

The method of claim 1, wherein R2 is hydrogen and R3 is alkyl.

### Claim 10 (depends on 1)

The method of claim 1, wherein R2 is AHB and R3 is alkyl.

### Claim 11 (depends on 10)

The method of claim 10, wherein said alkyl is methyl.

### Claim 12 (depends on 1)

The method of claim 1, wherein the compound is selected from the group consisting of:

### Claim 13 (depends on 1)

The method of claim 1, wherein the compound is selected from the group consisting of:

### Claim 14 (depends on 1)

The method of claim 1, wherein the compound is

### Claim 15 (depends on 1)

The method of claim 1, wherein the compound is

### Claim 16 (depends on 1)

The method of claim 1, wherein the compound is

### Claim 17 (depends on 1)

The method of claim 1, wherein said Rett syndrome is associated with a MECP2 premature stop codon mutation.

### Claim 18 (depends on 17)

The method of claim 17, wherein said mutation is a nonsense mutation.

### Claim 19 (depends on 18)

The method of claim 18, wherein said MECP2 nonsense mutation is selected from the group consisting of R168X, R255X, R270X and R294X.
